In addition, HIF-1α expression levels after platinum/gemcitabine therapy did not correlate with outcome of patients with stage II/III non-small cell lung cancer and HIF-1α expression was not associated with adverse effects or outcome in patients with pancreatic cancer [42]. Here, HIF1A is linked to non-small cell lung carcinoma.